Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 5
2007 2
2008 5
2009 2
2010 7
2011 4
2012 6
2013 10
2014 7
2015 5
2016 6
2017 5
2018 5
2019 11
2020 10
2021 14
2022 14
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).
Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kröger N, Wolschke C, Schleuning M, Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK. Burchert A, et al. Among authors: wolschke c. J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16. J Clin Oncol. 2020. PMID: 32673171 Clinical Trial.
Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation.
Gagelmann N, Badbaran A, Salit RB, Schroeder T, Gurnari C, Pagliuca S, Panagiota V, Rautenberg C, Cassinat B, Thol F, Wolschke C, Robin M, Heuser M, Rubio MT, Maciejewski JP, Reinhardt HC, Scott BL, Kröger N. Gagelmann N, et al. Among authors: wolschke c. Blood. 2023 Jun 8;141(23):2901-2911. doi: 10.1182/blood.2023019630. Blood. 2023. PMID: 36940410
Development of CAR-T cell therapies for multiple myeloma.
Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk FA, Fehse B, Kröger N. Gagelmann N, et al. Among authors: wolschke c. Leukemia. 2020 Sep;34(9):2317-2332. doi: 10.1038/s41375-020-0930-x. Epub 2020 Jun 22. Leukemia. 2020. PMID: 32572190 Review.
Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M.
Gurnari C, Gagelmann N, Badbaran A, Awada H, Dima D, Pagliuca S, D'Aveni-Piney M, Attardi E, Voso MT, Cerretti R, Wolschke C, Rubio MT, Maciejewski JP, Kröger N. Gurnari C, et al. Among authors: wolschke c. Leukemia. 2023 Mar;37(3):717-719. doi: 10.1038/s41375-023-01820-4. Epub 2023 Jan 28. Leukemia. 2023. PMID: 36709353 No abstract available.
Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway.
Brakert L, Berneking L, Both A, Berinson B, Huang J, Aepfelbacher M, Wolschke C, Wichmann D, Rohde H. Brakert L, et al. Among authors: wolschke c. J Glob Antimicrob Resist. 2023 Sep;34:59-62. doi: 10.1016/j.jgar.2023.06.003. Epub 2023 Jun 26. J Glob Antimicrob Resist. 2023. PMID: 37379881 Free article.
Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy.
Berger SC, Fehse B, Akyüz N, Geffken M, Wolschke C, Janson D, Gagelmann N, Luther M, Wichmann D, Frenzel C, Thayssen G, Alegiani A, Badbaran A, Zeschke S, Dierlamm J, Kröger N, Ayuk FA. Berger SC, et al. Among authors: wolschke c. Haematologica. 2023 Feb 1;108(2):444-456. doi: 10.3324/haematol.2022.281110. Haematologica. 2023. PMID: 35950534 Free PMC article.
117 results